查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1600591

细胞株开拓市场：按类型、来源、产品、应用分类 - 2025-2030 年全球预测

Cell Line Development Market by Type (Continuous Cell Lines, Hybridomas, Primary Cell Lines), Source (Amphibian, Insect, Mammalian), Product, Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

细胞株开拓市场2023年估值为56.9亿美元，预计2024年将达到64.9亿美元，复合年增长率为14.34%，预计到2030年将达到145.4亿美元。

细胞株开拓在生物製药研究和生产中发挥着至关重要的作用，创建了药物开发、基因研究和治疗应用所必需的细胞模型。这个过程涵盖初始细胞采购、基因操作和培养，对于单株抗体、疫苗和蛋白质的生产至关重要。该领域的需求在于其对个人化医疗、再生疗法和生技药品生产效率的核心作用。主要应用涵盖生物製药、生物技术和医疗保健领域，最终用户包括製药公司、医疗保健研究机构和学术机构。市场成长受到生技药品需求增加、细胞培养技术进步以及研发资金增加的显着影响。新的研发机会将重点放在开发用于癌症研究、精准医学和增强 CRISPR 技术的强大细胞株。鼓励公司投资自动化和一次性技术，以利用生产效率和扩充性。儘管具有成长潜力，但该领域面临一些限制，例如初始设置成本高、法律规范严格以及维持细胞株稳定性和重现性方面的挑战。 3D 细胞培养、连续处理和用于细胞株选择的人工智慧等创新有望提高製程效率和产品质量，为研究和开发提供成熟的途径。在生物加工的进步以及旨在简化管道的战略伙伴关係和联盟的增加的推动下，市场充满活力和竞争。随着情势的发展，企业必须成功平衡成本控制和技术创新，以保持竞争优势。新兴趋势凸显了整合尖端基因组技术和生物资讯学工具以优化细胞株特性和增强治疗效果的必要性，在细胞株开拓领域开闢新的适应症和市场为探索领导地位提供了前沿。

主要市场统计
基准年[2023] 56.9亿美元
预测年份 [2024] 64.9亿美元
预测年份 [2030] 145.4亿美元
复合年增长率（%） 14.34%

市场动态：快速发展的细胞株开拓市场的关键市场洞察

供需的动态交互作用正在改变细胞株开拓市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 由于应用范围扩大，对单株抗体的需求增加
    • 创新技术以及研究和政府机构的更多参与
    • 疫苗产量增加
  • 市场限制因素
    • 产品及应用认知度低，高成本
  • 市场机会
    • 感染性疾病的风险增加
    • 低收入国家的可能性
  • 市场挑战
    • 开发可靠且稳定的细胞株

波特的五力：驾驭细胞株开拓市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解细胞株开拓市场的外部影响

外部宏观环境因素在塑造细胞株开拓市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解细胞株开拓市场的竞争状况

细胞株开拓市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位矩阵细胞株开拓市场厂商绩效评估

FPNV定位矩阵是评估细胞株开拓市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。四个象限清楚且准确地划分供应商，帮助使用者辨识最能满足其策略目标的合作伙伴和解决方案。

本报告提供了涵盖关键重点领域的全面市场分析：

1. 市场渗透率：对当前市场环境的详细回顾，包括行业主要企业的大量资料。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 由于应用范围不断扩大，对单株抗体的需求不断增加
      • 创新技术以及研究和政府机构的更多参与
      • 疫苗产量增加
    • 抑制因素
      • 产品及应用认知度低，高成本
    • 机会
      • 感染性疾病的风险增加
      • 低收入国家的潜力
    • 任务
      • 开发可靠且稳定的细胞株
  • 市场区隔分析
    • 类型：连续细胞株係由于其稳健性和易于工作而越来越多地在研究活动中被采用。
    • 来源：越来越多地使用哺乳动物细胞株来生产治疗分子
    • 产品：将先进技术整合到细胞株开拓设备中
    • 应用：生物生产对可扩展且可靠的细胞株开拓策略的需求
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境
  • 客户客製化
    • 技术进步
      • 胺基甲基叶酸放大技术
      • 麸酰胺酸合成酶技术
      • 基于病毒的技术

第六章细胞株开拓市场：依类型

  • 连续性细胞株
  • 融合瘤
  • 初代细胞系
  • 重组细胞株

第 7 章细胞株开拓市场：依来源分类

  • 两栖类
  • 昆虫
  • 哺乳动物的

第 8 章细胞株开拓市场：副产品

  • 装置
    • 自动化系统
    • 反应器
    • 生物安全柜
    • 细胞计数器和活力测量系统
    • 离心机
    • 过滤系统
    • 培养箱
    • 显微镜
    • 仓储设备
  • 介质和试剂
    • 媒体
      • 最少所需介质
      • 减少血清培养基
      • 无血清培养基
    • 试剂
      • 缓衝液和化学品
      • 细胞分离试剂
      • 冻存试剂
      • 补充品和生长因子
    • 血清
      • 牛血清
      • 牛

第九章细胞株开拓市场：依应用分类

  • 生物生产
    • 诊断
    • 重组蛋白疗法
    • 疫苗生产
  • 药物发现
    • 疾病模型
    • 药物筛检与开发
    • 目标检验
  • 调查
  • 组织工程与再生医学
  • 毒性试验

第十章 北美和南美细胞株开拓市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太地区细胞株开拓市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲的细胞株开拓市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争场景分析
    • FairJourney Biologics 选择 Sphere Fluidics 的 Cyto-Mine 系统来推进细胞株开拓工作流程
    • 布鲁克公司和 Phenomex 宣布布鲁克以全现金交易收购 Phenomex 的最终协议
    • KBI Biopharma 推出 KBI PURE 平台，这是一种用于生物製药製造的微生物表现解决方案

公司名单

  • Boehringer Ingelheim International GmbH
  • Aragen Life Sciences Ltd.
  • Eurofins Scientific
  • Rentschler Biopharma SE
  • PromoCell GmbH
  • KBI Biopharma by JSR Life Sciences, LLC
  • FUJIFILM Diosynth Biotechnologies USA, Inc.
  • Thermo Fisher Scientific Inc.
  • Vista Biologicals Corporation
  • Merck KGaA
  • WuXi Biologics Co., Ltd.
  • Novartis AG
  • EuBiologics Co.,Ltd.
  • Lonza Group Ltd.
  • Syngene International Ltd.
  • Danaher Corporation
  • GenScript Biotech Corporation
  • GE HealthCare Technologies Inc.
  • Samsung Biologics Co., Ltd.
  • Catalent, Inc.
  • AGC Biologics
  • Corning Incorporated
  • Cyagen
  • Sartorius AG
  • Advanced Instruments, LLC
Product Code: MRR-43078BB92CCA

The Cell Line Development Market was valued at USD 5.69 billion in 2023, expected to reach USD 6.49 billion in 2024, and is projected to grow at a CAGR of 14.34%, to USD 14.54 billion by 2030.

Cell line development plays a pivotal role in biopharmaceutical research and production, creating essential cellular models for drug development, genetic research, and therapeutic applications. The process spans from initial cell sourcing to genetic manipulation and culturing, critical for producing monoclonal antibodies, vaccines, and proteins. This field's necessity lies in its centrality to personalized medicine, regenerative therapies, and biologics production efficiency. Key applications extend across biopharmaceutical, biotechnology, and healthcare sectors, with end-users including pharmaceutical companies, healthcare research organizations, and academic institutions. Market growth is significantly influenced by rising demand for biologics, advancements in cell culture technology, and increased funding for R&D. Emerging opportunities are noted in the development of robust cell lines for cancer research, precision medicine, and CRISPR technology enhancements. Companies are recommended to invest in automation and single-use technologies to capitalize on production efficiency and scalability. Despite its growth potential, the sector faces limitations such as high initial setup costs, stringent regulatory frameworks, and challenges in maintaining cell line stability and reproducibility. Innovations in 3D cell cultures, continuous processing, and artificial intelligence for cell line selection present ripe avenues for research and development, promising to enhance process efficiency and product quality. The market is dynamically competitive, driven by advancements in bioprocessing and increasing strategic partnerships and collaborations aimed at streamlining the cell line development pipeline. As the landscape evolves, companies must navigate the balance between cost management and technological innovation to maintain competitive advantage. Emerging trends highlight the necessity of integrating cutting-edge genomic techniques and bioinformatics tools to optimize cell line characteristics and enhance therapeutic outputs, offering a frontier for exploring new efficacies and market leadership in the cell line development domain.

KEY MARKET STATISTICS
Base Year [2023] USD 5.69 billion
Estimated Year [2024] USD 6.49 billion
Forecast Year [2030] USD 14.54 billion
CAGR (%) 14.34%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cell Line Development Market

The Cell Line Development Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increase Demand for Monoclonal Antibodies Owing to Increase Application
    • Innovative Technologies Coupled with Increased Participation of Research Institutes and Government Agency
    • Growing Rise in Vaccine Production
  • Market Restraints
    • Limited Awareness and High Cost Associated with The Product and Applications
  • Market Opportunities
    • Increasing Risk of Communicable Epidemics Diseases
    • Potential in Low-income Countries
  • Market Challenges
    • Developing Authentic and Stable Cell Lines

Porter's Five Forces: A Strategic Tool for Navigating the Cell Line Development Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cell Line Development Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cell Line Development Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cell Line Development Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cell Line Development Market

A detailed market share analysis in the Cell Line Development Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cell Line Development Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cell Line Development Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Cell Line Development Market, highlighting leading vendors and their innovative profiles. These include Boehringer Ingelheim International GmbH, Aragen Life Sciences Ltd., Eurofins Scientific, Rentschler Biopharma SE, PromoCell GmbH, KBI Biopharma by JSR Life Sciences, LLC, FUJIFILM Diosynth Biotechnologies U.S.A., Inc., Thermo Fisher Scientific Inc., Vista Biologicals Corporation, Merck KGaA, WuXi Biologics Co., Ltd., Novartis AG, EuBiologics Co.,Ltd., Lonza Group Ltd., Syngene International Ltd., Danaher Corporation, GenScript Biotech Corporation, GE HealthCare Technologies Inc., Samsung Biologics Co., Ltd., Catalent, Inc., AGC Biologics, Corning Incorporated, Cyagen, Sartorius AG, and Advanced Instruments, LLC.

Market Segmentation & Coverage

This research report categorizes the Cell Line Development Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Continuous Cell Lines, Hybridomas, Primary Cell Lines, and Recombinant Cell Lines.
  • Based on Source, market is studied across Amphibian, Insect, and Mammalian.
  • Based on Product, market is studied across Equipment and Media and Reagents. The Equipment is further studied across Automated Systems, Bioreactors, Biosafety Cabinets, Cell Counters and Viability Systems, Centrifuges, Filtration Systems, Incubators, Microscopes, and Storage Equipment. The Media and Reagents is further studied across Media, Reagents, and Serum. The Media is further studied across Minimum Essential Media, Reduced Serum Media, and Serum-free Media. The Reagents is further studied across Buffers and Chemicals, Cell Dissociation Reagents, Cryopreservative Reagents, and Supplements and Growth Factors. The Serum is further studied across Adult Bovine Serum and Fetal Bovine Serum.
  • Based on Application, market is studied across Bioproduction, Drug Discovery, Research, Tissue Engineering & Regenerative Medicine, and Toxicity Testing. The Bioproduction is further studied across Diagnostics, Recombinant Protein Therapeutics, and Vaccine Production. The Drug Discovery is further studied across Disease Modeling, Drug Screening and Development, and Target Validation.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increase Demand for Monoclonal Antibodies Owing to Increase Application
      • 5.1.1.2. Innovative Technologies Coupled with Increased Participation of Research Institutes and Government Agency
      • 5.1.1.3. Growing Rise in Vaccine Production
    • 5.1.2. Restraints
      • 5.1.2.1. Limited Awareness and High Cost Associated with The Product and Applications
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing Risk of Communicable Epidemics Diseases
      • 5.1.3.2. Potential in Low-income Countries
    • 5.1.4. Challenges
      • 5.1.4.1. Developing Authentic and Stable Cell Lines
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Increasing adoption of continuous cell lines in research activities due to their robustness and ease of work
    • 5.2.2. Source: Rising utilization of mammalian sources of cell lines for the production of therapeutic molecules
    • 5.2.3. Product: Integration of advanced technologies in equipment for cell line development
    • 5.2.4. Application: Need for scalable and reliable cell line development strategies for bioproduction
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental
  • 5.5. Client Customization
    • 5.5.1. Technology Advancement
      • 5.5.1.1. Methotrexate Amplification Technology
      • 5.5.1.2. Glutamine Synthatase Technology
      • 5.5.1.3. Viral-Based Technology

6. Cell Line Development Market, by Type

  • 6.1. Introduction
  • 6.2. Continuous Cell Lines
  • 6.3. Hybridomas
  • 6.4. Primary Cell Lines
  • 6.5. Recombinant Cell Lines

7. Cell Line Development Market, by Source

  • 7.1. Introduction
  • 7.2. Amphibian
  • 7.3. Insect
  • 7.4. Mammalian

8. Cell Line Development Market, by Product

  • 8.1. Introduction
  • 8.2. Equipment
    • 8.2.1. Automated Systems
    • 8.2.2. Bioreactors
    • 8.2.3. Biosafety Cabinets
    • 8.2.4. Cell Counters and Viability Systems
    • 8.2.5. Centrifuges
    • 8.2.6. Filtration Systems
    • 8.2.7. Incubators
    • 8.2.8. Microscopes
    • 8.2.9. Storage Equipment
  • 8.3. Media and Reagents
    • 8.3.1. Media
      • 8.3.1.1. Minimum Essential Media
      • 8.3.1.2. Reduced Serum Media
      • 8.3.1.3. Serum-free Media
    • 8.3.2. Reagents
      • 8.3.2.1. Buffers and Chemicals
      • 8.3.2.2. Cell Dissociation Reagents
      • 8.3.2.3. Cryopreservative Reagents
      • 8.3.2.4. Supplements and Growth Factors
    • 8.3.3. Serum
      • 8.3.3.1. Adult Bovine Serum
      • 8.3.3.2. Fetal Bovine Serum

9. Cell Line Development Market, by Application

  • 9.1. Introduction
  • 9.2. Bioproduction
    • 9.2.1. Diagnostics
    • 9.2.2. Recombinant Protein Therapeutics
    • 9.2.3. Vaccine Production
  • 9.3. Drug Discovery
    • 9.3.1. Disease Modeling
    • 9.3.2. Drug Screening and Development
    • 9.3.3. Target Validation
  • 9.4. Research
  • 9.5. Tissue Engineering & Regenerative Medicine
  • 9.6. Toxicity Testing

10. Americas Cell Line Development Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Cell Line Development Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Cell Line Development Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Sphere Fluidics' Cyto-Mine System Selected by FairJourney Biologics To Advance Cell Line Development Workflows
    • 13.3.2. Bruker Corporation and PhenomeX Inc. Announce Definitive Agreement for Bruker to Acquire PhenomeX in All-Cash Transaction
    • 13.3.3. KBI Biopharma Unveils KBI PUREplatform, a Microbial Expression Offering for Biopharmaceutical Manufacturing

Companies Mentioned

  • 1. Boehringer Ingelheim International GmbH
  • 2. Aragen Life Sciences Ltd.
  • 3. Eurofins Scientific
  • 4. Rentschler Biopharma SE
  • 5. PromoCell GmbH
  • 6. KBI Biopharma by JSR Life Sciences, LLC
  • 7. FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
  • 8. Thermo Fisher Scientific Inc.
  • 9. Vista Biologicals Corporation
  • 10. Merck KGaA
  • 11. WuXi Biologics Co., Ltd.
  • 12. Novartis AG
  • 13. EuBiologics Co.,Ltd.
  • 14. Lonza Group Ltd.
  • 15. Syngene International Ltd.
  • 16. Danaher Corporation
  • 17. GenScript Biotech Corporation
  • 18. GE HealthCare Technologies Inc.
  • 19. Samsung Biologics Co., Ltd.
  • 20. Catalent, Inc.
  • 21. AGC Biologics
  • 22. Corning Incorporated
  • 23. Cyagen
  • 24. Sartorius AG
  • 25. Advanced Instruments, LLC

LIST OF FIGURES

  • FIGURE 1. CELL LINE DEVELOPMENT MARKET RESEARCH PROCESS
  • FIGURE 2. CELL LINE DEVELOPMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS CELL LINE DEVELOPMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS CELL LINE DEVELOPMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES CELL LINE DEVELOPMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES CELL LINE DEVELOPMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CELL LINE DEVELOPMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC CELL LINE DEVELOPMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CELL LINE DEVELOPMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CELL LINE DEVELOPMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. CELL LINE DEVELOPMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. CELL LINE DEVELOPMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CELL LINE DEVELOPMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CELL LINE DEVELOPMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY CONTINUOUS CELL LINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY HYBRIDOMAS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY PRIMARY CELL LINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY RECOMBINANT CELL LINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY AMPHIBIAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY INSECT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY MAMMALIAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY AUTOMATED SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY BIOREACTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY BIOSAFETY CABINETS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY CELL COUNTERS AND VIABILITY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY CENTRIFUGES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY FILTRATION SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY INCUBATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY MICROSCOPES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY STORAGE EQUIPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA AND REAGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY MINIMUM ESSENTIAL MEDIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY REDUCED SERUM MEDIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY SERUM-FREE MEDIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY REAGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY BUFFERS AND CHEMICALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY CELL DISSOCIATION REAGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY CRYOPRESERVATIVE REAGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY SUPPLEMENTS AND GROWTH FACTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY SERUM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY ADULT BOVINE SERUM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY FETAL BOVINE SERUM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY SERUM, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA AND REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY BIOPRODUCTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY RECOMBINANT PROTEIN THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY VACCINE PRODUCTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY BIOPRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY DISEASE MODELING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 53. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY DRUG SCREENING AND DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 54. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY TARGET VALIDATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 55. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 56. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 57. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 58. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY TOXICITY TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 59. AMERICAS CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. AMERICAS CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 61. AMERICAS CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 62. AMERICAS CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 63. AMERICAS CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA AND REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 64. AMERICAS CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA, 2018-2030 (USD MILLION)
  • TABLE 65. AMERICAS CELL LINE DEVELOPMENT MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 66. AMERICAS CELL LINE DEVELOPMENT MARKET SIZE, BY SERUM, 2018-2030 (USD MILLION)
  • TABLE 67. AMERICAS CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. AMERICAS CELL LINE DEVELOPMENT MARKET SIZE, BY BIOPRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 69. AMERICAS CELL LINE DEVELOPMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 70. AMERICAS CELL LINE DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 71. ARGENTINA CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. ARGENTINA CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 73. ARGENTINA CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 74. ARGENTINA CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 75. ARGENTINA CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA AND REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 76. ARGENTINA CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA, 2018-2030 (USD MILLION)
  • TABLE 77. ARGENTINA CELL LINE DEVELOPMENT MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 78. ARGENTINA CELL LINE DEVELOPMENT MARKET SIZE, BY SERUM, 2018-2030 (USD MILLION)
  • TABLE 79. ARGENTINA CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. ARGENTINA CELL LINE DEVELOPMENT MARKET SIZE, BY BIOPRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 81. ARGENTINA CELL LINE DEVELOPMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 82. BRAZIL CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. BRAZIL CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 84. BRAZIL CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 85. BRAZIL CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 86. BRAZIL CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA AND REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 87. BRAZIL CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA, 2018-2030 (USD MILLION)
  • TABLE 88. BRAZIL CELL LINE DEVELOPMENT MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 89. BRAZIL CELL LINE DEVELOPMENT MARKET SIZE, BY SERUM, 2018-2030 (USD MILLION)
  • TABLE 90. BRAZIL CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. BRAZIL CELL LINE DEVELOPMENT MARKET SIZE, BY BIOPRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 92. BRAZIL CELL LINE DEVELOPMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 93. CANADA CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. CANADA CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 95. CANADA CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 96. CANADA CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 97. CANADA CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA AND REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 98. CANADA CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA, 2018-2030 (USD MILLION)
  • TABLE 99. CANADA CELL LINE DEVELOPMENT MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 100. CANADA CELL LINE DEVELOPMENT MARKET SIZE, BY SERUM, 2018-2030 (USD MILLION)
  • TABLE 101. CANADA CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. CANADA CELL LINE DEVELOPMENT MARKET SIZE, BY BIOPRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 103. CANADA CELL LINE DEVELOPMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 104. MEXICO CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. MEXICO CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 106. MEXICO CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 107. MEXICO CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 108. MEXICO CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA AND REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 109. MEXICO CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA, 2018-2030 (USD MILLION)
  • TABLE 110. MEXICO CELL LINE DEVELOPMENT MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 111. MEXICO CELL LINE DEVELOPMENT MARKET SIZE, BY SERUM, 2018-2030 (USD MILLION)
  • TABLE 112. MEXICO CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. MEXICO CELL LINE DEVELOPMENT MARKET SIZE, BY BIOPRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 114. MEXICO CELL LINE DEVELOPMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 115. UNITED STATES CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. UNITED STATES CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 117. UNITED STATES CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 118. UNITED STATES CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 119. UNITED STATES CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA AND REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 120. UNITED STATES CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA, 2018-2030 (USD MILLION)
  • TABLE 121. UNITED STATES CELL LINE DEVELOPMENT MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 122. UNITED STATES CELL LINE DEVELOPMENT MARKET SIZE, BY SERUM, 2018-2030 (USD MILLION)
  • TABLE 123. UNITED STATES CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 124. UNITED STATES CELL LINE DEVELOPMENT MARKET SIZE, BY BIOPRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 125. UNITED STATES CELL LINE DEVELOPMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 126. UNITED STATES CELL LINE DEVELOPMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA AND REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA, 2018-2030 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC CELL LINE DEVELOPMENT MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC CELL LINE DEVELOPMENT MARKET SIZE, BY SERUM, 2018-2030 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC CELL LINE DEVELOPMENT MARKET SIZE, BY BIOPRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC CELL LINE DEVELOPMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC CELL LINE DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 139. AUSTRALIA CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. AUSTRALIA CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 141. AUSTRALIA CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 142. AUSTRALIA CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 143. AUSTRALIA CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA AND REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 144. AUSTRALIA CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA, 2018-2030 (USD MILLION)
  • TABLE 145. AUSTRALIA CELL LINE DEVELOPMENT MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 146. AUSTRALIA CELL LINE DEVELOPMENT MARKET SIZE, BY SERUM, 2018-2030 (USD MILLION)
  • TABLE 147. AUSTRALIA CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 148. AUSTRALIA CELL LINE DEVELOPMENT MARKET SIZE, BY BIOPRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 149. AUSTRALIA CELL LINE DEVELOPMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 150. CHINA CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. CHINA CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 152. CHINA CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 153. CHINA CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 154. CHINA CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA AND REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 155. CHINA CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA, 2018-2030 (USD MILLION)
  • TABLE 156. CHINA CELL LINE DEVELOPMENT MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 157. CHINA CELL LINE DEVELOPMENT MARKET SIZE, BY SERUM, 2018-2030 (USD MILLION)
  • TABLE 158. CHINA CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 159. CHINA CELL LINE DEVELOPMENT MARKET SIZE, BY BIOPRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 160. CHINA CELL LINE DEVELOPMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 161. INDIA CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. INDIA CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 163. INDIA CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 164. INDIA CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 165. INDIA CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA AND REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 166. INDIA CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA, 2018-2030 (USD MILLION)
  • TABLE 167. INDIA CELL LINE DEVELOPMENT MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 168. INDIA CELL LINE DEVELOPMENT MARKET SIZE, BY SERUM, 2018-2030 (USD MILLION)
  • TABLE 169. INDIA CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 170. INDIA CELL LINE DEVELOPMENT MARKET SIZE, BY BIOPRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 171. INDIA CELL LINE DEVELOPMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 172. INDONESIA CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. INDONESIA CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 174. INDONESIA CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 175. INDONESIA CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 176. INDONESIA CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA AND REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 177. INDONESIA CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA, 2018-2030 (USD MILLION)
  • TABLE 178. INDONESIA CELL LINE DEVELOPMENT MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 179. INDONESIA CELL LINE DEVELOPMENT MARKET SIZE, BY SERUM, 2018-2030 (USD MILLION)
  • TABLE 180. INDONESIA CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 181. INDONESIA CELL LINE DEVELOPMENT MARKET SIZE, BY BIOPRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 182. INDONESIA CELL LINE DEVELOPMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 183. JAPAN CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. JAPAN CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 185. JAPAN CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 186. JAPAN CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 187. JAPAN CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA AND REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 188. JAPAN CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA, 2018-2030 (USD MILLION)
  • TABLE 189. JAPAN CELL LINE DEVELOPMENT MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 190. JAPAN CELL LINE DEVELOPMENT MARKET SIZE, BY SERUM, 2018-2030 (USD MILLION)
  • TABLE 191. JAPAN CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 192. JAPAN CELL LINE DEVELOPMENT MARKET SIZE, BY BIOPRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 193. JAPAN CELL LINE DEVELOPMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 194. MALAYSIA CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. MALAYSIA CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 196. MALAYSIA CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 197. MALAYSIA CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 198. MALAYSIA CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA AND REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 199. MALAYSIA CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA, 2018-2030 (USD MILLION)
  • TABLE 200. MALAYSIA CELL LINE DEVELOPMENT MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 201. MALAYSIA CELL LINE DEVELOPMENT MARKET SIZE, BY SERUM, 2018-2030 (USD MILLION)
  • TABLE 202. MALAYSIA CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 203. MALAYSIA CELL LINE DEVELOPMENT MARKET SIZE, BY BIOPRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 204. MALAYSIA CELL LINE DEVELOPMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 205. PHILIPPINES CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. PHILIPPINES CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 207. PHILIPPINES CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 208. PHILIPPINES CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 209. PHILIPPINES CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA AND REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 210. PHILIPPINES CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA, 2018-2030 (USD MILLION)
  • TABLE 211. PHILIPPINES CELL LINE DEVELOPMENT MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 212. PHILIPPINES CELL LINE DEVELOPMENT MARKET SIZE, BY SERUM, 2018-2030 (USD MILLION)
  • TABLE 213. PHILIPPINES CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 214. PHILIPPINES CELL LINE DEVELOPMENT MARKET SIZE, BY BIOPRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 215. PHILIPPINES CELL LINE DEVELOPMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 216. SINGAPORE CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. SINGAPORE CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 218. SINGAPORE CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 219. SINGAPORE CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 220. SINGAPORE CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA AND REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 221. SINGAPORE CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA, 2018-2030 (USD MILLION)
  • TABLE 222. SINGAPORE CELL LINE DEVELOPMENT MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 223. SINGAPORE CELL LINE DEVELOPMENT MARKET SIZE, BY SERUM, 2018-2030 (USD MILLION)
  • TABLE 224. SINGAPORE CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 225. SINGAPORE CELL LINE DEVELOPMENT MARKET SIZE, BY BIOPRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 226. SINGAPORE CELL LINE DEVELOPMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 227. SOUTH KOREA CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. SOUTH KOREA CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 229. SOUTH KOREA CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 230. SOUTH KOREA CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 231. SOUTH KOREA CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA AND REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 232. SOUTH KOREA CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA, 2018-2030 (USD MILLION)
  • TABLE 233. SOUTH KOREA CELL LINE DEVELOPMENT MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 234. SOUTH KOREA CELL LINE DEVELOPMENT MARKET SIZE, BY SERUM, 2018-2030 (USD MILLION)
  • TABLE 235. SOUTH KOREA CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 236. SOUTH KOREA CELL LINE DEVELOPMENT MARKET SIZE, BY BIOPRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 237. SOUTH KOREA CELL LINE DEVELOPMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 238. TAIWAN CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 239. TAIWAN CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 240. TAIWAN CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 241. TAIWAN CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 242. TAIWAN CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA AND REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 243. TAIWAN CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA, 2018-2030 (USD MILLION)
  • TABLE 244. TAIWAN CELL LINE DEVELOPMENT MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 245. TAIWAN CELL LINE DEVELOPMENT MARKET SIZE, BY SERUM, 2018-2030 (USD MILLION)
  • TABLE 246. TAIWAN CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 247. TAIWAN CELL LINE DEVELOPMENT MARKET SIZE, BY BIOPRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 248. TAIWAN CELL LINE DEVELOPMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 249. THAILAND CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 250. THAILAND CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 251. THAILAND CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 252. THAILAND CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 253. THAILAND CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA AND REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 254. THAILAND CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA, 2018-2030 (USD MILLION)
  • TABLE 255. THAILAND CELL LINE DEVELOPMENT MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 256. THAILAND CELL LINE DEVELOPMENT MARKET SIZE, BY SERUM, 2018-2030 (USD MILLION)
  • TABLE 257. THAILAND CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 258. THAILAND CELL LINE DEVELOPMENT MARKET SIZE, BY BIOPRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 259. THAILAND CELL LINE DEVELOPMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 260. VIETNAM CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 261. VIETNAM CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 262. VIETNAM CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 263. VIETNAM CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 264. VIETNAM CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA AND REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 265. VIETNAM CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA, 2018-2030 (USD MILLION)
  • TABLE 266. VIETNAM CELL LINE DEVELOPMENT MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 267. VIETNAM CELL LINE DEVELOPMENT MARKET SIZE, BY SERUM, 2018-2030 (USD MILLION)
  • TABLE 268. VIETNAM CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 269. VIETNAM CELL LINE DEVELOPMENT MARKET SIZE, BY BIOPRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 270. VIETNAM CELL LINE DEVELOPMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA AND REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA, 2018-2030 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA CELL LINE DEVELOPMENT MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA CELL LINE DEVELOPMENT MARKET SIZE, BY SERUM, 2018-2030 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA CELL LINE DEVELOPMENT MARKET SIZE, BY BIOPRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA CELL LINE DEVELOPMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA CELL LINE DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 283. DENMARK CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 284. DENMARK CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 285. DENMARK CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 286. DENMARK CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 287. DENMARK CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA AND REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 288. DENMARK CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA, 2018-2030 (USD MILLION)
  • TABLE 289. DENMARK CELL LINE DEVELOPMENT MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 290. DENMARK CELL LINE DEVELOPMENT MARKET SIZE, BY SERUM, 2018-2030 (USD MILLION)
  • TABLE 291. DENMARK CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 292. DENMARK CELL LINE DEVELOPMENT MARKET SIZE, BY BIOPRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 293. DENMARK CELL LINE DEVELOPMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 294. EGYPT CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 295. EGYPT CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 296. EGYPT CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 297. EGYPT CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 298. EGYPT CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA AND REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 299. EGYPT CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA, 2018-2030 (USD MILLION)
  • TABLE 300. EGYPT CELL LINE DEVELOPMENT MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 301. EGYPT CELL LINE DEVELOPMENT MARKET SIZE, BY SERUM, 2018-2030 (USD MILLION)
  • TABLE 302. EGYPT CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 303. EGYPT CELL LINE DEVELOPMENT MARKET SIZE, BY BIOPRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 304. EGYPT CELL LINE DEVELOPMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 305. FINLAND CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 306. FINLAND CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 307. FINLAND CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 308. FINLAND CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 309. FINLAND CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA AND REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 310. FINLAND CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA, 2018-2030 (USD MILLION)
  • TABLE 311. FINLAND CELL LINE DEVELOPMENT MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 312. FINLAND CELL LINE DEVELOPMENT MARKET SIZE, BY SERUM, 2018-2030 (USD MILLION)
  • TABLE 313. FINLAND CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 314. FINLAND CELL LINE DEVELOPMENT MARKET SIZE, BY BIOPRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 315. FINLAND CELL LINE DEVELOPMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 316. FRANCE CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 317. FRANCE CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 318. FRANCE CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 319. FRANCE CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 320. FRANCE CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA AND REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 321. FRANCE CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA, 2018-2030 (USD MILLION)
  • TABLE 322. FRANCE CELL LINE DEVELOPMENT MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 323. FRANCE CELL LINE DEVELOPMENT MARKET SIZE, BY SERUM, 2018-2030 (USD MILLION)
  • TABLE 324. FRANCE CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 325. FRANCE CELL LINE DEVELOPMENT MARKET SIZE, BY BIOPRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 326. FRANCE CELL LINE DEVELOPMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 327. GERMANY CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 328. GERMANY CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 329. GERMANY CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 330. GERMANY CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 331. GERMANY CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA AND REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 332. GERMANY CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA, 2018-2030 (USD MILLION)
  • TABLE 333. GERMANY CELL LINE DEVELOPMENT MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 334. GERMANY CELL LINE DEVELOPMENT MARKET SIZE, BY SERUM, 2018-2030 (USD MILLION)
  • TABLE 335. GERMANY CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 336. GERMANY CELL LINE DEVELOPMENT MARKET SIZE, BY BIOPRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 337. GERMANY CELL LINE DEVELOPMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 338. ISRAEL CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 339. ISRAEL CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 340. ISRAEL CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 341. ISRAEL CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 342. ISRAEL CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA AND REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 343. ISRAEL CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA, 2018-2030 (USD MILLION)
  • TABLE 344. ISRAEL CELL LINE DEVELOPMENT MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 345. ISRAEL CELL LINE DEVELOPMENT MARKET SIZE, BY SERUM, 2018-2030 (USD MILLION)
  • TABLE 346. ISRAEL CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (U